SSX2IP and acute myeloid leukemia: Previous studies indicated that SSX2IP is an acute myeloid leukemia-associated antigen, as analysis of clinical cases showed that the expression of SSX2IP was identified in the serum of 33% patients with acute myeloid leukaemia (AML), but not in healthy volunteers[9].